Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 10/22/2014 AVERAGE SEVERITY GRADES[b]

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:23

First Dose M/F: NA / NA

Lab: NCTR

C Number: MG96005

Lock Date: Not Entered.

Cage Range: ΑII

Date Range: ΑII

Reasons For Removal: ΑII

Removal Date Range: ΑII

Treatment Groups: ΑII

Study Gender: Both

PWG Approval Date NONE

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:23

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:23

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Disposition Summary						
Animals Initially In Study	54	50	50	50	50	50
Early Deaths						
Moribund	6	5	6	12	7	10
Natural Death	9	3		6	7	5
Survivors						
Moribund	2		1		2	1
Natural Death	1	1		1		2
Terminal Sacrifice	36	41	43	31	34	32
Animals Examined Microscopically	54	50	50	50	50	50
ALIMENTARY SYSTEM						
Esophagus	(53)	(50)	(50)	(50)	(50)	(47)
Dilatation				1 [4.0]		
Hyperkeratosis	4 [2.0]	1 [2.0]		7 [1.6]	2 [1.5]	1 [2.0]
Intestine Large, Cecum	(44)	(46)	(50)	(46)	(45)	(42)
Autolysis				1 [4.0]		
Hyperplasia, Lymphoid	2 [2.0]		1 [2.0]	1 [2.0]		1 [2.0]
Polyarteritis		1 [4.0]		1 [4.0]		
Intestine Large, Colon	(46)	(46)	(50)	(46)	(45)	(43)
Autolysis				1 [4.0]		
Hyperplasia, Lymphoid	1 [2.0]		1 [2.0]	1 [3.0]		
Inflammation, Suppurative						
Polyarteritis				1 [3.0]		
Intestine Large, Rectum	(37)	(42)	(43)	(34)	(37)	(33)
Intestine Small, Duodenum	(46)	(45)	(50)	(46)	(45)	(43)
Autolysis				1 [4.0]		
Hemorrhage				1 [2.0]		
Inflammation, Suppurative				1 [3.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:24

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:24

First Dose M/F: NA / NA

CD Rat MALE	F1 0PPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Necrosis				1 [2.0]		
Serosa, Polyarteritis	1 [3.0]					
Intestine Small, Ileum	(43)	(47)	(50)	(44)	(44)	(42)
Autolysis			1 [3.0]			
Hyperplasia, Lymphoid	1 [2.0]	1 [2.0]	1 [2.0]			
Polyarteritis		1 [4.0]		1 [2.0]		
Intestine Small, Jejunum	(44)	(45)	(50)	(43)	(42)	(42)
Autolysis			1 [3.0]			
Hyperplasia, Lymphoid	2 [2.0]		1 [2.0]			
Polyarteritis		1 [4.0]		1 [2.0]		
Liver	(51)	(48)	(50)	(48)	(49)	(47)
Adventitia, Hemorrhage				1 [3.0]		
Angiectasis	2 [1.5]	7 [1.9]	3 [1.7]	2 [1.5]	4 [2.0]	4 [2.3]
Autolysis	3 [2.7]			3 [2.3]	2 [2.5]	1 [3.0]
Basophilic Focus	3	5	4	5	2	4
Basophilic Focus, Multiple		2		1		
Bile Duct, Hyperplasia	17 [1.3]	13 [1.2]	9 [1.1]	19 [1.2]	14 [1.1]	8 [1.3]
Biliar Tract, Fibrosis	7 [1.3]	13 [1.1]	7 [1.0]	16 [1.1]	12 [1.1]	9 [1.0]
Capsule, Fibrosis	1 [2.0]		1 [2.0]	1 [1.0]		
Capsule, Hemorrhage		1 [2.0]				
Capsule, Inflammation, Chronic			1 [1.0]			
Cholangiofibrosis			1 [3.0]			
Clear Cell Focus	1	1				
Clear Cell Focus, Multiple		1		1	1	1
Cyst			2	1		1
Degeneration, Cystic	2 [1.5]	6 [1.5]	4 [1.5]	1 [1.0]	3 [1.7]	3 [1.7]
Developmental Malformation	1	1			1	
Eosinophilic Focus	1	1	2			3
Eosinophilic Focus, Multiple	3	4		1	2	1

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:24

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:24

First Dose M/F: NA / NA

CD Rat MALE	F1 0PPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Fatty Change					1 [2.0]	
Granuloma, Multiple			1 [4.0]			
Hematopoietic Cell Proliferation	1 [1.0]					1 [1.0]
Hemorrhage	1 [2.0]	2 [2.5]		1 [2.0]		
Hepatodiaphragmatic Nodule	2	1		3		2
Infiltration Cellular, Lymphocyte	8 [1.1]	2 [1.0]	2 [1.0]	8 [1.0]	1 [1.0]	3 [1.0]
Inflammation, Chronic Active	9 [1.1]	7 [1.0]	6 [1.2]	6 [1.0]	6 [1.0]	9 [1.1]
Mineralization	1 [1.0]					
Mixed Cell Focus						
Necrosis	3 [1.3]		3 [1.7]	3 [1.0]		3 [1.0]
Pigmentation		1 [1.0]				
Polyarteritis		1 [4.0]		1 [4.0]		
Tension Lipidosis	2 [3.0]	1 [1.0]		1 [3.0]	1 [3.0]	1 [3.0]
Vacuolization Cytoplasmic	5 [1.6]	4 [1.5]	6 [1.8]	2 [1.5]	3 [1.3]	5 [1.4]
Mesentery	(1)	(1)	(0)	(1)	(1)	(1)
Fat, Inflammation, Chronic						
Fat, Necrosis	1 [3.0]	1 [4.0]		1 [4.0]	1 [4.0]	1 [3.0]
Oral Mucosa	(0)	(0)	(0)	(1)	(0)	(0)
Pancreas	(50)	(49)	(50)	(49)	(49)	(46)
Accessory Spleen						1
Acinar Cell, Degeneration	33 [2.1]	33 [1.7]	34 [2.1]	27 [1.9]	32 [1.9]	33 [1.8]
Acinar Cell, Hyperplasia		1 [2.0]	1 [4.0]	1 [3.0]		
Adventitia, Polyarteritis						1 [2.0]
Autolysis	3 [2.7]			3 [2.7]	2 [3.0]	1 [2.0]
Basophilic Focus	1		2			
Infiltration Cellular, Lymphocyte	1 [1.0]		1 [1.0]	2 [1.5]		
Inflammation, Chronic				1 [3.0]		2 [2.0]
Inflammation, Chronic Active	3 [1.3]					1 [2.0]
Inflammation, Granulomatous	1 [2.0]					-

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:24

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:24

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Pigmentation	2 [1.0]	1 [2.0]			1 [1.0]	2 [1.0]
Polyarteritis		1 [3.0]		1 [4.0]		
Salivary Glands	(49)	(49)	(50)	(47)	(49)	(46)
Acinar Cell, Hyperplasia				1 [2.0]	1 [2.0]	
Atrophy					1 [3.0]	
Hyperplasia, Lymphoid					1 [4.0]	
Mineralization			1 [2.0]			
Stomach, Forestomach	(45)	(46)	(50)	(46)	(47)	(45)
Cyst, Squamous	1					
Epithelium, Hyperplasia			1 [2.0]			
Hyperkeratosis		1 [1.0]				
Hyperplasia	1 [2.0]	2 [2.0]				
Inflammation, Chronic Active	1 [2.0]					
Keratin Cyst			1			
Polyarteritis				1 [2.0]		
Submucosa, Edema					1 [3.0]	
Ulcer		1 [3.0]				
Stomach, Glandular	(45)	(47)	(50)	(44)	(46)	(44)
Epithelium, Hyperplasia		1 [4.0]				
Polyarteritis				1 [2.0]		
CARDIOVASCULAR SYSTEM						
Blood Vessel	(53)	(50)	(50)	(50)	(50)	(48)
Polyarteritis		1 [4.0]				
Thrombosis		1 [4.0]				
Heart	(52)	(50)	(50)	(50)	(48)	(48)
Autolysis	1 [4.0]			1 [4.0]		1 [2.0]
Bacterium						
Cardiomyopathy	13 [1.2]	30 [1.4]	29 [1.4]	21 [1.1]	23 [1.3]	27 [1.2]
Endocardium, Hyperplasia						1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:24

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:24

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Endocardium, Inflammation, Chronic Active	e					1 [2.0]
Epicardium, Hyperplasia	1 [1.0]					
Inflammation, Suppurative						
Metaplasia, Osseous	1 [1.0]		5 [1.0]		2 [1.0]	
Mineralization	1 [1.0]					
Myocardium, Necrosis						
Polyarteritis		1 [4.0]		2 [1.5]	1 [2.0]	
Thrombosis						1
ENDOCRINE SYSTEM						
Adrenal Cortex	(49)	(47)	(50)	(48)	(47)	(46)
Accessory Adrenal Cortical Nodule	2	2		3		3
Angiectasis	1 [2.0]		1 [2.0]	2 [1.5]	2 [2.0]	
Atrophy			3 [3.7]			
Autolysis					1 [3.0]	
Bilateral, Hyperplasia		1 [1.0]				
Capsule, Fibrosis			1 [2.0]		1 [1.0]	
Cyst		1		1		
Degeneration, Cystic	3 [2.7]	1 [2.0]	2 [1.5]	2 [1.5]	1 [2.0]	6 [1.8]
Hyperplasia	2 [2.0]	7 [1.6]	2 [1.5]	2 [1.5]	5 [2.2]	3 [1.3]
Hypertrophy	2 [1.0]	7 [1.3]	8 [1.9]	3 [1.3]	6 [1.7]	7 [1.6]
Infiltration Cellular, Lymphocyte			1 [2.0]			
Metaplasia, Osseous						1 [3.0]
Pigmentation			1 [2.0]	1 [2.0]		
Vacuolization Cytoplasmic	14 [1.6]	25 [1.3]	36 [1.4]	13 [1.4]	26 [1.3]	22 [1.9]
Adrenal Medulla	(47)	(49)	(50)	(49)	(47)	(46)
Bilateral, Hyperplasia	2 [2.5]	2 [1.0]	2 [1.0]	1 [1.0]		1 [1.0]
Cyst	1					
Hemorrhage						
Hyperplasia	6 [1.8]	8 [2.1]	11 [1.5]	5 [1.2]	6 [1.5]	5 [2.2]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:25

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:25

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTI
Hyperplasia, Focal		1 [1.0]				
Infiltration Cellular, Lymphocyte						1 [2.0]
Vacuolization Cytoplasmic						1 [2.0]
Islets, Pancreatic	(49)	(49)	(50)	(49)	(49)	(46)
Autolysis						
Hyperplasia	23 [1.4]	23 [1.3]	18 [1.4]	21 [1.2]	19 [1.2]	15 [1.5]
Parathyroid Gland	(47)	(47)	(47)	(47)	(48)	(47)
Bilateral, Hyperplasia	2 [2.0]	5 [1.8]	2 [2.0]		1 [1.0]	2 [2.5]
Hyperplasia	3 [1.7]	6 [1.7]	8 [1.5]	2 [1.5]	9 [1.6]	8 [1.3]
Pituitary Gland	(49)	(46)	(50)	(49)	(49)	(48)
Autolysis				1 [3.0]	2 [3.0]	3 [4.0]
Pars Distalis, Cyst	3	6	6	5	6	3
Pars Distalis, Cyst, Multiple	1	2	2	1	1	1
Pars Distalis, Hyperplasia	13 [1.9]	17 [2.2]	11 [1.7]	13 [1.8]	19 [1.7]	19 [1.8]
Pars Intermed, Cyst			1			
Pars Intermed, Cyst, Multiple	1	1				
Pars Intermed, Hyperplasia						1 [2.0]
Thyroid Gland	(49)	(47)	(50)	(46)	(46)	(44)
Autolysis	1 [2.0]			1 [4.0]		
C Cell, Hyperplasia	7 [1.3]	1 [1.0]	1 [1.0]	9 [1.4]	2 [2.0]	
Cyst, Squamous	7	8	4	3	2	4
Follicular Cel, Cyst					2	
Follicular Cel, Hyperplasia					1 [3.0]	
Infiltration Cellular, Lymphocyte	2 [1.0]					
Inflammation, Chronic	1 [2.0]					
Polyarteritis		1 [3.0]				
Vacuolization Cytoplasmic		<u> </u>				2 [3.0]
ENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(1)	(1)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:25

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:25

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
GENITAL SYSTEM						
Coagulating Gland	(47)	(49)	(50)	(45)	(45)	(45)
Adventitia, Polyarteritis		1 [3.0]				
Atrophy	2 [3.5]		2 [3.0]	2 [2.5]	3 [2.0]	3 [2.0]
Autolysis		1 [3.0]			1 [2.0]	
Concretion		1				
Degeneration	1 [2.0]					
Developmental Malformation	4	4	4	4	2	4
Dilatation			1 [3.0]			
Hyperplasia	1 [2.0]				1 [2.0]	
Infiltration Cellular, Lymphocyte				1 [2.0]		
Inflammation, Suppurative						1 [4.0]
Interstitium, Inflammation, Chronic		1 [3.0]				
Epididymis	(51)	(48)	(50)	(49)	(50)	(47)
Adventitia, Polyarteritis		1 [2.0]				
Atrophy	1 [4.0]					
Autolysis	1 [2.0]					
Degeneration	2 [2.0]	4 [2.0]	5 [2.4]	7 [1.9]	1 [3.0]	5 [2.2]
Granuloma Sperm		1 [4.0]				
Hypospermia	7 [3.7]	4 [4.0]	6 [3.7]	4 [4.0]	1 [4.0]	7 [4.0]
Infiltration Cellular, Lymphocyte	4 [1.0]	5 [1.0]	1 [1.0]	2 [1.0]	1 [1.0]	4 [1.3]
Inflammation, Chronic Active			1 [2.0]			
Inflammation, Suppurative						1 [4.0]
Polyarteritis			1 [2.0]	1 [3.0]		
Penis	(0)	(1)	(0)	(0)	(1)	(0)
Concretion		1			1	
Hemorrhage					1 [1.0]	
Preputial Gland	(49)	(48)	(49)	(49)	(50)	(48)
Abscess			1 [4.0]	3 [4.0]	1 [4.0]	1 [4.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:25

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:25

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Atrophy	1 [2.0]				2 [2.5]	1 [2.0]
Autolysis	1 [3.0]	1 [4.0]		1 [3.0]		1 [4.0]
Cyst		1				
Duct, Dilatation	4 [3.8]	4 [3.3]	7 [4.0]	5 [4.0]	8 [3.4]	3 [3.7]
Foreign Body			1			
Infiltration Cellular, Lymphocyte	21 [1.5]	21 [1.3]	21 [1.4]	10 [1.3]	15 [1.5]	16 [1.4]
Inflammation, Chronic						1 [2.0]
Inflammation, Chronic Active						
Inflammation, Suppurative	15 [3.0]	16 [2.6]	21 [3.1]	22 [3.1]	20 [3.2]	22 [3.0]
Keratin Cyst				1		
Necrosis			1 [3.0]			
Parenchym Cell, Degeneration	16 [1.7]	20 [1.7]	27 [1.9]	18 [1.7]	21 [2.0]	23 [2.0]
Prostate	(8)	(9)	(2)	(2)	(8)	(6)
Prostate, Dorsal Lobe	(48)	(49)	(50)	(49)	(49)	(50)
Autolysis		1 [3.0]		1 [3.0]	2 [3.5]	4 [3.8]
Cyst			2			
Degeneration	2 [1.5]		4 [2.0]	2 [1.5]	1 [2.0]	2 [2.5]
Hyperplasia		1 [2.0]				
Infiltration Cellular, Lymphocyte	2 [1.0]	4 [1.3]	2 [1.0]		1 [1.0]	2 [1.0]
Inflammation, Suppurative	31 [2.0]	31 [1.9]	43 [2.1]	41 [2.3]	34 [2.1]	40 [2.1]
Interstitium, Fibrosis		1 [4.0]				
Polyarteritis		1 [4.0]		2 [2.0]		
Prostate, Ventral Lobe	(48)	(49)	(50)	(48)	(49)	(48)
Autolysis				1 [3.0]	3 [3.0]	2 [4.0]
Degeneration	13 [1.9]	9 [2.6]	13 [2.3]	7 [2.1]	5 [1.8]	5 [2.2]
Hyperplasia	7 [2.1]	4 [1.5]	8 [2.1]	9 [1.8]	9 [2.3]	4 [1.5]
Infiltration Cellular, Lymphocyte	7 [1.1]	4 [1.3]	6 [1.2]	4 [1.0]	6 [1.0]	4 [2.0]
Inflammation				1 [4.0]		
Inflammation, Suppurative	6 [2.2]	7 [2.0]	6 [2.0]	4 [2.5]	6 [2.0]	10 [2.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:25

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:25

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Interstitium, Fibrosis		1 [3.0]		1 [1.0]		
Polyarteritis				1 [2.0]		
Rete Testes	(44)	(47)	(47)	(44)	(50)	(46)
Dilatation	3 [2.3]		3 [1.7]	3 [2.0]	3 [1.3]	3 [2.0]
Fibrosis	1 [3.0]	1 [3.0]	2 [2.5]	1 [3.0]		1 [2.0]
Spermatocele			1 [4.0]			
Seminal Vesicle	(47)	(48)	(50)	(45)	(43)	(45)
Atrophy	3 [3.3]	4 [2.0]	5 [2.6]	5 [2.8]	2 [2.0]	3 [2.7]
Autolysis	1 [4.0]	1 [3.0]				1 [4.0]
Dilatation		2 [2.5]	2 [2.0]	2 [2.0]	1 [2.0]	1 [3.0]
Fibrosis			1 [2.0]			
Hyperplasia		3 [2.3]	1 [2.0]			1 [3.0]
Inflammation, Chronic			1 [1.0]		1 [2.0]	
Inflammation, Chronic Active						1 [2.0]
Inflammation, Suppurative		1 [2.0]				1 [4.0]
Testes	(50)	(50)	(50)	(49)	(49)	(47)
Artery, Mineralization				1 [3.0]		
Autolysis	1 [4.0]			1 [4.0]		4 [3.5]
Interstit Cell, Hyperplasia	1 [3.0]					
Polyarteritis	2 [2.0]			1 [2.0]	1 [1.0]	1 [2.0]
Seminif Tub, Degeneration	31 [2.3]	26 [1.8]	26 [2.1]	17 [1.9]	32 [1.6]	23 [2.0]
HEMATOPOIETIC SYSTEM						
Bone Marrow	(49)	(49)	(50)	(48)	(48)	(47)
Autolysis	1 [4.0]	1 [4.0]				1 [2.0]
Erythroid Cell, Hyperplasia		2 [2.0]	1 [2.0]	4 [2.8]	1 [2.0]	1 [2.0]
Hypocellularity	2 [2.0]	1 [2.0]	2 [3.5]	3 [2.3]		1 [4.0]
Myeloid Cell, Hyperplasia	3 [2.3]	2 [2.0]	3 [2.0]	8 [3.0]	3 [2.7]	4 [3.3]
Lymph Node	(15)	(13)	(16)	(8)	(14)	(14)
Adventitia, Pancreatic, Polyarteritis	1 [3.0]	•		•	•	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:25

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:25

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTI
Adventitia, Renal, Hemorrhage	1 [4.0]					
Deep Cervical, Autolysis	1 [4.0]					
Degeneration, Cystic		1 [4.0]				
Infiltration Cellular, Plasma Cell		1 [2.0]				
Inguinal, Hyperplasia, Lymphoid			1 [2.0]			2 [3.0]
Inguinal, Infiltration Cellular, Plasma Cell			2 [3.0]			2 [3.5]
Lumbar, Autolysis	1 [4.0]					
Lumbar, Degeneration, Cystic	6 [3.7]	4 [3.3]	7 [3.7]	4 [3.3]	9 [3.0]	7 [2.9]
Lumbar, Hemorrhage	1 [3.0]					
Lumbar, Hyperplasia, Lymphoid	3 [3.7]	3 [2.3]	4 [2.3]		1 [3.0]	7 [2.9]
Lumbar, Infiltration Cellular, Plasma Cell	7 [3.9]	5 [3.2]	9 [3.8]	4 [4.0]	6 [3.7]	10 [3.4]
Mediastinal, Hemorrhage						
Mediastinal, Hyperplasia, Lymphoid					1 [2.0]	
Mediastinal, Infiltration Cellular, Plasma Cell	1 [3.0]	1 [3.0]	1 [4.0]			
Pancreatic, Hemorrhage						1 [1.0]
Pancreatic, Hyperplasia, Lymphoid	1 [2.0]	3 [2.3]	1 [2.0]	1 [2.0]	1 [2.0]	
Pancreatic, Infiltration Cellular, Plasma Cell			1 [3.0]	2 [2.5]		1 [3.0]
Pancreatic, Inflammation, Granulomatous	1 [2.0]	1 [2.0]			1 [1.0]	
Pancreatic, Pigmentation						1 [1.0]
Popliteal, Degeneration, Cystic					1 [2.0]	
Popliteal, Hyperplasia, Lymphoid		1 [3.0]	1 [2.0]		2 [3.0]	
Popliteal, Infiltration Cellular, Plasma Cell		1 [4.0]	1 [2.0]	1 [4.0]	2 [3.0]	
Renal, Autolysis	1 [4.0]					
Renal, Degeneration, Cystic					1 [3.0]	2 [4.0]
Renal, Fibrosis						1 [4.0]
Renal, Hyperplasia, Lymphoid			1 [2.0]		1 [4.0]	1 [3.0]
Renal, Infiltration Cellular, Plasma Cell			1 [4.0]		1 [4.0]	2 [4.0]
Renal, Pigmentation	1 [2.0]					
mph Node, Mandibular	(52)	(50)	(49)	(46)	(49)	(45)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:25

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:25

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Autolysis	3 [3.3]	1 [4.0]		1 [2.0]		
Degeneration, Cystic	7 [3.3]	4 [2.8]	9 [2.4]	7 [2.7]	6 [2.2]	4 [2.8]
Hemorrhage				1 [2.0]		
Hyperplasia, Lymphoid	23 [2.1]	12 [2.3]	13 [2.4]	19 [2.3]	17 [2.2]	11 [2.3]
Infiltration Cellular, Plasma Cell	30 [2.5]	21 [2.3]	31 [2.5]	33 [2.8]	28 [2.4]	21 [2.6]
Pigmentation				1 [2.0]		
Lymph Node, Mesenteric	(48)	(50)	(50)	(46)	(47)	(45)
Autolysis		2 [3.5]		1 [2.0]	1 [4.0]	
Degeneration, Cystic	3 [4.0]	4 [4.0]	1 [4.0]	6 [3.0]	1 [2.0]	2 [2.5]
Hemorrhage			1 [3.0]	1 [2.0]		
Hyperplasia, Lymphoid	14 [1.9]	6 [2.5]	8 [2.4]	11 [2.0]	7 [2.0]	4 [1.8]
Infiltration Cellular, Mast Cell	2 [2.0]			2 [2.0]	2 [2.0]	
Infiltration Cellular, Plasma Cell	3 [2.0]	4 [3.3]	2 [4.0]	4 [2.8]	1 [2.0]	2 [2.0]
Inflammation, Granulomatous	14 [1.6]	17 [1.7]	27 [1.7]	17 [1.8]	22 [1.5]	22 [1.7]
Pigmentation	1 [1.0]					1 [4.0]
Polyarteritis		1 [4.0]		2 [3.0]		
Spleen	(52)	(48)	(50)	(48)	(50)	(47)
Accessory Spleen	1					
Adventitia, Polyarteritis				1 [3.0]		
Autolysis	3 [2.7]			3 [2.0]	2 [2.5]	3 [2.3]
Capsule, Fibrosis	1 [2.0]			1 [2.0]		
Depletion Lymphoid			1 [2.0]	2 [4.0]		1 [4.0]
Hematopoietic Cell Proliferation	8 [2.0]	12 [2.2]	8 [2.1]	9 [2.6]	12 [2.0]	13 [1.3]
Hematopoietic Cell Proliferation Erythrocytic						
Hyperplasia, Lymphoid	2 [1.5]	1 [4.0]	3 [1.7]	3 [2.0]	3 [2.3]	2 [2.5]
Hyperplasia, Stromal				1 [3.0]		
Inflammation, Chronic Active						1 [4.0]
Necrosis						1 [4.0]
Pigmentation	30 [2.2]	30 [2.1]	24 [2.5]	31 [2.5]	35 [2.2]	27 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:26

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:26

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Red Pulp, Hyperplasia			1 [4.0]			
Thymus	(42)	(44)	(45)	(42)	(47)	(40)
Adventitia, Polyarteritis		1 [3.0]				
Atrophy	36 [3.8]	41 [4.0]	43 [3.9]	39 [3.8]	41 [3.9]	38 [3.9]
Autolysis		1 [4.0]		1 [4.0]	1 [4.0]	1 [4.0]
Epithel Cell, Hyperplasia					2 [2.5]	
Hemorrhage				1 [3.0]		
Hyperplasia, Lymphoid	1 [4.0]				1 [3.0]	
INTEGUMENTARY SYSTEM						
Mammary Gland	(41)	(43)	(40)	(42)	(42)	(34)
Alveolus, Hyperplasia	3 [1.7]	2 [1.5]	6 [1.7]	8 [1.4]	1 [1.0]	1 [2.0]
Autolysis	1 [3.0]					
Degeneration	21 [2.6]	24 [2.8]	12 [2.8]	14 [2.9]	17 [2.6]	18 [2.4]
Duct, Dilatation	1 [4.0]	2 [3.0]	3 [2.7]	3 [2.7]	2 [2.5]	1 [3.0]
Galactocele		1 [4.0]	1 [4.0]			
Hemorrhage		1 [4.0]				
Hyperplasia, Mast Cell						
Infiltration Cellular, Mast Cell						1 [2.0]
Inflammation, Chronic						
Inflammation, Granulomatous		1 [4.0]				
Inflammation, Suppurative		1 [2.0]				
Lactation	3 [2.0]	1 [2.0]	3 [2.0]	7 [2.0]	3 [2.0]	3 [2.0]
Skin	(51)	(49)	(50)	(50)	(50)	(50)
Abscess	1 [4.0]	1 [4.0]	1 [4.0]	1 [4.0]		
Angiectasis			1 [2.0]	1 [3.0]		
Autolysis	1 [3.0]					
Cyst		1				
Cyst Epithelial Inclusion	2		2	2	3	
Dermis, Fibrosis						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:26

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:26

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Epidermis, Hyperplasia	5 [2.2]	2 [3.0]	2 [3.0]	1 [2.0]	6 [2.5]	
Epidermis, Ulcer	1 [4.0]					
Fibrosis	1 [3.0]	1 [4.0]				1 [4.0]
Foreign Body				1		1
Hemorrhage		1 [2.0]	1 [2.0]			1 [2.0]
Hyperkeratosis	5 [2.0]	2 [2.5]	2 [2.5]	1 [2.0]	6 [2.2]	
Inflammation, Chronic	2 [1.5]	1 [1.0]	1 [2.0]	1 [2.0]	1 [1.0]	1 [2.0]
Inflammation, Chronic Active	7 [2.4]	8 [3.4]	7 [2.4]	5 [2.8]	7 [2.9]	10 [2.8]
Inflammation, Granulomatous						1 [4.0]
Inflammation, Pyogranulomat	1 [4.0]			1 [4.0]		
Inflammation, Suppurative	22 [3.9]	21 [3.9]	29 [3.8]	19 [3.8]	21 [4.0]	24 [4.0]
Necrosis	4 [2.5]	2 [3.5]	1 [2.0]	4 [2.5]	3 [2.7]	3 [2.3]
MUSCULOSKELETAL SYSTEM						
Bone, Cranium	(0)	(0)	(0)	(0)	(0)	(1)
Bone, Femur	(53)	(50)	(50)	(50)	(49)	(50)
Hyperostosis	1 [2.0]					
Necrosis			1 [4.0]			
Skeletal Muscle	(0)	(0)	(0)	(1)	(0)	(0)
Cyst						
Fibrosis			,		,	
NERVOUS SYSTEM						
Brain, Brain Stem	(50)	(48)	(50)	(48)	(50)	(48)
Autolysis	1 [3.0]				1 [2.0]	1 [4.0]
Compression	7 [1.7]	3 [2.0]	5 [2.2]	5 [2.6]	4 [2.0]	4 [2.3]
Cyst		· -		-	-	1
Gliosis					1 [2.0]	
Hemorrhage	1 [1.0]			1 [2.0]	1 [2.0]	1 [2.0]
Brain, Cerebellum	(50)	(48)	(50)	(47)	(49)	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:26

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:26

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Autolysis	1 [3.0]				1 [2.0]	
Gliosis	1 [1.0]					
Hemorrhage	1 [1.0]			2 [3.5]	1 [2.0]	
Hydrocephalus	1 [4.0]	1 [3.0]	1 [1.0]		2 [1.5]	1 [2.0]
Brain, Cerebrum	(50)	(48)	(50)	(48)	(50)	(48)
Autolysis	1 [3.0]				1 [2.0]	
Compression						1 [2.0]
Developmental Malformation						1
Ectopic Tissue						1
Gliosis						1 [2.0]
Hemorrhage				1 [2.0]	2 [2.0]	1 [2.0]
Hydrocephalus	3 [3.0]	1 [3.0]	1 [1.0]	3 [1.7]	2 [1.5]	3 [2.0]
Infiltration Cellular, Lymphocyte				1 [2.0]		
Meninges, Congestion	1 [3.0]					
Meninges, Fibrosis						
Meninges, Hemorrhage	1 [3.0]					
Mineralization				1 [2.0]		1 [2.0]
RESPIRATORY SYSTEM						
Lung	(49)	(47)	(50)	(47)	(48)	(44)
Alveolar Epith, Hyperplasia	3 [1.7]	3 [2.0]	5 [2.6]	1 [1.0]	3 [1.3]	2 [1.5]
Artery, Mineralization	3 [1.7]	6 [1.2]	8 [1.3]	9 [1.1]	5 [1.2]	3 [1.3]
Autolysis	1 [4.0]			2 [3.0]	1 [2.0]	
Congestion						
Cyst	1					
Edema	1 [3.0]					
Hemorrhage	3 [3.0]		1 [4.0]			1 [4.0]
Infiltration Cellular, Histiocyte	15 [1.6]	19 [1.8]	20 [1.7]	16 [1.3]	21 [1.5]	14 [1.6]
Infiltration Cellular, Histiocytic		1 [2.0]			1 [1.0]	
Infiltration Cellular, Lymphocyte	1 [1.0]		1 [1.0]		1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:26

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:26

First Dose M/F: NA / NA

Lab: NCTR

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Inflammation, Chronic		1 [2.0]			1 [2.0]	
Inflammation, Suppurative				1 [3.0]		
Metaplasia, Osseous	2 [1.0]	3 [1.3]	6 [1.0]	3 [1.0]	3 [1.3]	4 [1.0]
Peribronchial, Hyperplasia, Lymphoid				1 [2.0]		
Pigmentation				1 [1.0]		
Pleura, Fibrosis			1 [1.0]			
Pleura, Hyperplasia			1 [1.0]			
Pleura, Inflammation, Chronic			1 [1.0]			
Polyarteritis				2 [2.0]		
Nose	(48)	(48)	(50)	(48)	(47)	(45)
Autolysis	1 [3.0]			1 [3.0]	1 [2.0]	
Cyst						
Foreign Body			1		1	1
Fungus					1	
Hemorrhage	1 [3.0]					
Hyperkeratosis	1 [2.0]					
Inflammation, Chronic Active	1 [2.0]	1 [1.0]	1 [2.0]		3 [2.7]	3 [2.0]
Inflammation, Suppurative	3 [2.3]	1 [1.0]	4 [1.5]	4 [2.3]	5 [1.4]	8 [1.8]
Keratin Cyst	1			1		1
Metaplasia, Osseous				1 [1.0]		
Necrosis					2 [3.0]	
Squam Epithel, Hyperplasia	2 [2.5]					
Squam Epithel, Metaplasia	1 [2.0]					
Ulcer	1 [3.0]					
Upper Molar, Inflammation, Chronic Active	2 [2.0]			2 [1.5]	2 [2.0]	
Trachea	(47)	(47)	(50)	(46)	(47)	(46)
Cyst, Squamous						
Epithelium, Hyperplasia				1 [2.0]		

SPECIAL SENSES SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Ear	(0)	(0)	(0)	(0)	(0)	(0)
Eye	(37)	(42)	(43)	(35)	(37)	(33)
Antr Chamber, Hemorrhage						1 [4.0]
Antr Chamber, Inflammation, Suppurative						1 [4.0]
Bilateral, Retina, Atrophy	6 [2.0]	4 [2.0]	10 [1.9]	6 [1.3]	5 [1.6]	4 [1.8]
Cataract				2 [2.0]	1 [1.0]	
Cornea, Degeneration						1 [4.0]
Cornea, Inflammation, Suppurative						1 [4.0]
Cornea, Ulcer						1 [4.0]
Inflammation, Chronic	1 [2.0]					
Inflammation, Chronic Active				1 [2.0]		
Inflammation, Suppurative				1 [4.0]		
Retina, Atrophy	5 [1.6]	2 [2.0]	1 [2.0]	1 [1.0]	2 [2.0]	
Harderian Gland	(39)	(42)	(43)	(37)	(39)	(33)
Degeneration	1 [1.0]	2 [1.0]	1 [2.0]	1 [1.0]	1 [2.0]	
Epithelium, Hyperplasia					1 [1.0]	
Infiltration Cellular, Lymphocyte	5 [1.4]	5 [1.4]	3 [1.0]	4 [1.0]	1 [1.0]	3 [1.0]
Inflammation, Chronic					1 [2.0]	
Pigmentation				1 [4.0]		
Lacrimal Gland	(10)	(9)	(10)	(14)	(14)	(12)
Degeneration					1 [2.0]	1 [4.0]
Ectopic Harderian	10	9	10	14	13	12
Infiltration Cellular, Lymphocyte					1 [2.0]	1 [2.0]
Inflammation, Chronic Active					1 [3.0]	
Zymbal's Gland	(0)	(1)	(0)	(1)	(0)	(1)
Inflammation, Suppurative						1 [4.0]
RINARY SYSTEM						
Kidney	(48)	(48)	(50)	(48)	(48)	(46)
Accumulation, Hyaline Droplet	1 [4.0]			1 [4.0]		1 [4.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Autolysis	1 [2.0]	1 [3.0]		4 [3.3]	3 [4.0]	3 [3.7]
Bacterium		1 [4.0]				
Capsule, Fatty Change		1	3	2	2	4
Capsule, Fibrosis		1 [2.0]				
Congestion	1 [2.0]				1 [3.0]	
Cortex, Cyst	24	26	22	29	27	22
Fatty Change			1 [2.0]			
Fibrosis				1 [1.0]	1 [2.0]	1 [1.0]
Hyperplasia, Tubular	1 [1.0]		2 [3.0]			
Infiltration Cellular, Lymphocyte			2 [1.5]	5 [1.0]	2 [1.0]	2 [1.0]
Inflammation, Chronic	1 [1.0]	1 [1.0]		1 [1.0]	1 [1.0]	1 [1.0]
Inflammation, Chronic Active						1 [4.0]
Inflammation, Suppurative		1 [3.0]				
Medulla, Cyst	1					
Mineralization			1 [2.0]			
Nephropathy, Chronic	41 [1.5]	41 [1.5]	40 [1.5]	37 [1.8]	39 [1.5]	38 [2.0]
Pelvis, Dilatation	2 [2.0]			1 [4.0]	1 [2.0]	3 [2.0]
Pelvis, Hyperplasia	5 [1.8]	4 [1.5]	6 [1.7]	2 [2.0]	4 [1.5]	5 [2.0]
Pelvis, Inflammation, Suppurative					1 [2.0]	2 [3.5]
Pelvis, Mineralization		1 [2.0]	1 [2.0]		1 [2.0]	
Polyarteritis				1 [2.0]		
Polycystic Kidney					1 [3.0]	
Renal Tubule, Dilatation	3 [2.0]			2 [2.0]	1 [2.0]	
Renal Tubule, Inflammation, Suppurative	1 [2.0]		1 [2.0]	1 [2.0]		1 [2.0]
Renal Tubule, Mineralization	1 [1.0]			4 [1.8]		1 [2.0]
lrethra	(0)	(0)	(1)	(1)	(1)	(1)
Congestion						1 [2.0]
Irinary Bladder	(47)	(48)	(50)	(46)	(48)	(46)
Autolysis				1 [4.0]	1 [3.0]	1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

First Dose M/F: NA / NA

Time Report Requested: 17:23:27

CAS Number: 446-72-0

CD Rat MALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Dilatation		1 [4.0]	1 [4.0]			1 [4.0]
Hemorrhage	1 [2.0]			2 [1.5]		1 [3.0]
Inflammation, Chronic Active					1 [3.0]	
Transit Epithe, Hyperplasia					1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

Lab: NCTR

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Disposition Summary	
Animals Initially In Study	50
Early Deaths	
Moribund	5
Natural Death	7
Survivors	
Moribund	
Natural Death	
Terminal Sacrifice	38
Animals Examined Microscopically	50
ALIMENTARY SYSTEM	
Esophagus	(49)
Dilatation	
Hyperkeratosis	3 [2.3]
Intestine Large, Cecum	(44)
Autolysis	
Hyperplasia, Lymphoid	2 [2.0]
Polyarteritis	
Intestine Large, Colon	(46)
Autolysis	1 [4.0]
Hyperplasia, Lymphoid	2 [2.0]
Inflammation, Suppurative	1 [4.0]
Polyarteritis	1 [3.0]
Intestine Large, Rectum	(39)
Intestine Small, Duodenum	(45)
Autolysis	
Hemorrhage	
Inflammation, Suppurative	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Necrosis	
Serosa, Polyarteritis	
Intestine Small, Ileum	(43)
Autolysis	
Hyperplasia, Lymphoid	2 [2.0]
Polyarteritis	
Intestine Small, Jejunum	(42)
Autolysis	
Hyperplasia, Lymphoid	
Polyarteritis	
Liver	(48)
Adventitia, Hemorrhage	
Angiectasis	7 [1.9]
Autolysis	
Basophilic Focus	1
Basophilic Focus, Multiple	
Bile Duct, Hyperplasia	13 [1.2]
Biliar Tract, Fibrosis	9 [1.0]
Capsule, Fibrosis	1 [2.0]
Capsule, Hemorrhage	
Capsule, Inflammation, Chronic	
Cholangiofibrosis	
Clear Cell Focus	
Clear Cell Focus, Multiple	
Cyst	1
Degeneration, Cystic	2 [1.5]
Developmental Malformation	
Eosinophilic Focus	1
Eosinophilic Focus, Multiple	2

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Fatty Change	
Granuloma, Multiple	
Hematopoietic Cell Proliferation	2 [1.0]
Hemorrhage	1 [2.0]
Hepatodiaphragmatic Nodule	2
Infiltration Cellular, Lymphocyte	7 [1.0]
Inflammation, Chronic Active	10 [1.0]
Mineralization	
Mixed Cell Focus	1
Necrosis	4 [1.0]
Pigmentation	
Polyarteritis	
Tension Lipidosis	
Vacuolization Cytoplasmic	4 [1.5]
Mesentery	(1)
Fat, Inflammation, Chronic	1 [1.0]
Fat, Necrosis	
Oral Mucosa	(0)
Pancreas	(48)
Accessory Spleen	
Acinar Cell, Degeneration	30 [1.9]
Acinar Cell, Hyperplasia	
Adventitia, Polyarteritis	
Autolysis	2 [3.0]
Basophilic Focus	
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic	
Inflammation, Chronic Active	
Inflammation, Granulomatous	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Pigmentation	2 [1.5]
Polyarteritis	1 [4.0]
Salivary Glands	(50)
Acinar Cell, Hyperplasia	
Atrophy	
Hyperplasia, Lymphoid	
Mineralization	
Stomach, Forestomach	(49)
Cyst, Squamous	
Epithelium, Hyperplasia	
Hyperkeratosis	
Hyperplasia	
Inflammation, Chronic Active	
Keratin Cyst	
Polyarteritis	
Submucosa, Edema	
Ulcer	
Stomach, Glandular	(45)
Epithelium, Hyperplasia	
Polyarteritis	
CARDIOVASCULAR SYSTEM	
Blood Vessel	(49)
Polyarteritis	,
Thrombosis	
Heart	(50)
Autolysis	
Bacterium	1 [4.0]
Cardiomyopathy	16 [1.3]
Endocardium, Hyperplasia	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1	500PPM/CTL
Endocardium, Inflammation, Chronic Active		
Epicardium, Hyperplasia		
Inflammation, Suppurative		1 [4.0]
Metaplasia, Osseous		
Mineralization		
Myocardium, Necrosis		1 [4.0]
Polyarteritis		
Thrombosis		1 [4.0]
ENDOCRINE SYSTEM		
Adrenal Cortex		(46)
Accessory Adrenal Cortical Nodule		1
Angiectasis		1 [2.0]
Atrophy		1 [4.0]
Autolysis		
Bilateral, Hyperplasia		
Capsule, Fibrosis		
Cyst		
Degeneration, Cystic		7 [2.1]
Hyperplasia		1 [1.0]
Hypertrophy		3 [2.7]
Infiltration Cellular, Lymphocyte		
Metaplasia, Osseous		
Pigmentation		1 [2.0]
Vacuolization Cytoplasmic		17 [1.5]
Adrenal Medulla		(45)
Bilateral, Hyperplasia		
Cyst		
Hemorrhage		1 [4.0]
Hyperplasia		2 [1.5]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Hyperplasia, Focal	
Infiltration Cellular, Lymphocyte	
Vacuolization Cytoplasmic	
Islets, Pancreatic	(48)
Autolysis	1 [4.0]
Hyperplasia	23 [1.2]
Parathyroid Gland	(46)
Bilateral, Hyperplasia	
Hyperplasia	6 [2.2]
Pituitary Gland	(48)
Autolysis	
Pars Distalis, Cyst	4
Pars Distalis, Cyst, Multiple	1
Pars Distalis, Hyperplasia	20 [2.4]
Pars Intermed, Cyst	
Pars Intermed, Cyst, Multiple	
Pars Intermed, Hyperplasia	
Thyroid Gland	(48)
Autolysis	
C Cell, Hyperplasia	5 [1.6]
Cyst, Squamous	2
Follicular Cel, Cyst	
Follicular Cel, Hyperplasia	
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic	
Polyarteritis	
Vacuolization Cytoplasmic	
GENERAL BODY SYSTEM	
Tissue NOS	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:27

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:27

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
GENITAL SYSTEM	
Coagulating Gland	(47)
Adventitia, Polyarteritis	
Atrophy	5 [2.4]
Autolysis	1 [2.0]
Concretion	
Degeneration	1 [3.0]
Developmental Malformation	2
Dilatation	
Hyperplasia	
Infiltration Cellular, Lymphocyte	
Inflammation, Suppurative	2 [4.0]
Interstitium, Inflammation, Chronic	
Epididymis	(49)
Adventitia, Polyarteritis	
Atrophy	1 [3.0]
Autolysis	
Degeneration	5 [2.0]
Granuloma Sperm	1 [4.0]
Hypospermia	4 [4.0]
Infiltration Cellular, Lymphocyte	1 [1.0]
Inflammation, Chronic Active	
Inflammation, Suppurative	
Polyarteritis	1 [2.0]
Penis	(0)
Concretion	
Hemorrhage	
Preputial Gland	(49)
Abscess	1 [4.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Atrophy	1 [2.0]
Autolysis	
Cyst	
Duct, Dilatation	6 [3.5]
Foreign Body	
Infiltration Cellular, Lymphocyte	15 [1.4]
Inflammation, Chronic	
Inflammation, Chronic Active	2 [2.0]
Inflammation, Suppurative	16 [3.3]
Keratin Cyst	
Necrosis	
Parenchym Cell, Degeneration	16 [2.0]
Prostate	(3)
Prostate, Dorsal Lobe	(49)
Autolysis	2 [2.5]
Cyst	2
Degeneration	1 [1.0]
Hyperplasia	
Infiltration Cellular, Lymphocyte	1 [1.0]
Inflammation, Suppurative	40 [2.1]
Interstitium, Fibrosis	
Polyarteritis	
Prostate, Ventral Lobe	(48)
Autolysis	2 [2.5]
Degeneration	9 [2.6]
Hyperplasia	11 [1.6]
Infiltration Cellular, Lymphocyte	4 [1.0]
Inflammation	
Inflammation, Suppurative	7 [1.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Interstitium, Fibrosis	
Polyarteritis	
Rete Testes	(49)
Dilatation	3 [3.0]
Fibrosis	
Spermatocele	
Seminal Vesicle	(47)
Atrophy	9 [2.6]
Autolysis	1 [4.0]
Dilatation	1 [2.0]
Fibrosis	
Hyperplasia	1 [2.0]
Inflammation, Chronic	
Inflammation, Chronic Active	
Inflammation, Suppurative	1 [1.0]
Testes	(50)
Artery, Mineralization	
Autolysis	
Interstit Cell, Hyperplasia	1 [2.0]
Polyarteritis	1 [2.0]
Seminif Tub, Degeneration	26 [1.8]
HEMATOPOIETIC SYSTEM	
Bone Marrow	(49)
Autolysis	(15)
Erythroid Cell, Hyperplasia	3 [3.0]
Hypocellularity	2 [2.5]
Myeloid Cell, Hyperplasia	3 [2.0]
Lymph Node	(9)
Adventitia, Pancreatic, Polyarteritis	. ,

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1	500PPM/CTL
Adventitia, Renal, Hemorrhage		
Deep Cervical, Autolysis		
Degeneration, Cystic		
Infiltration Cellular, Plasma Cell		1 [4.0]
Inguinal, Hyperplasia, Lymphoid		
Inguinal, Infiltration Cellular, Plasma Cell		
Lumbar, Autolysis		
Lumbar, Degeneration, Cystic		3 [3.0]
Lumbar, Hemorrhage		
Lumbar, Hyperplasia, Lymphoid		
Lumbar, Infiltration Cellular, Plasma Cell		5 [3.6]
Mediastinal, Hemorrhage		1 [3.0]
Mediastinal, Hyperplasia, Lymphoid		
Mediastinal, Infiltration Cellular, Plasma Cell		
Pancreatic, Hemorrhage		
Pancreatic, Hyperplasia, Lymphoid		
Pancreatic, Infiltration Cellular, Plasma Cell		
Pancreatic, Inflammation, Granulomatous		
Pancreatic, Pigmentation		
Popliteal, Degeneration, Cystic		
Popliteal, Hyperplasia, Lymphoid		
Popliteal, Infiltration Cellular, Plasma Cell		
Renal, Autolysis		
Renal, Degeneration, Cystic		1 [4.0]
Renal, Fibrosis		
Renal, Hyperplasia, Lymphoid		
Renal, Infiltration Cellular, Plasma Cell		1 [3.0]
Renal, Pigmentation		
Lymph Node, Mandibular		(48)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Autolysis	
Degeneration, Cystic	6 [2.3]
Hemorrhage	
Hyperplasia, Lymphoid	20 [2.1]
Infiltration Cellular, Plasma Cell	28 [2.7]
Pigmentation	
Lymph Node, Mesenteric	(46)
Autolysis	
Degeneration, Cystic	4 [2.8]
Hemorrhage	1 [2.0]
Hyperplasia, Lymphoid	14 [1.9]
Infiltration Cellular, Mast Cell	5 [2.2]
Infiltration Cellular, Plasma Cell	3 [2.3]
Inflammation, Granulomatous	16 [1.5]
Pigmentation	1 [2.0]
Polyarteritis	
Spleen	(49)
Accessory Spleen	
Adventitia, Polyarteritis	
Autolysis	
Capsule, Fibrosis	
Depletion Lymphoid	3 [3.7]
Hematopoietic Cell Proliferation	11 [2.2]
Hematopoietic Cell Proliferation Erythrocytic	1 [3.0]
Hyperplasia, Lymphoid	2 [1.5]
Hyperplasia, Stromal	1 [4.0]
Inflammation, Chronic Active	
Necrosis	
Pigmentation	28 [2.3]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE F1 500PPM/0	CTL
Hyperplasia	
(45)	
, Polyarteritis	
44 [3.9]	
ell, Hyperplasia	
ge	
sia, Lymphoid	
ARY SYSTEM	
land (45)	
Hyperplasia 9 [1.4]	
tion 20 [2.8]	
tation 1 [4.0]	
ele 1 [4.0]	
ge	
sia, Mast Cell 1 [2.0]	
Cellular, Mast Cell	
ion, Chronic 1 [4.0]	
ion, Granulomatous	
ion, Suppurative	
3 [2.0]	
(50)	
is	
nelial Inclusion 2	
ibrosis 1 [4.0]	
elle 1 [4.0] age sia, Mast Cell 1 [2.0] Cellular, Mast Cell cion, Chronic 1 [4.0] cion, Granulomatous cion, Suppurative 3 [2.0] (50) sis	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Epidermis, Hyperplasia	2 [2.0]
Epidermis, Ulcer	
Fibrosis	
Foreign Body	
Hemorrhage	1 [3.0]
Hyperkeratosis	3 [2.7]
Inflammation, Chronic	1 [2.0]
Inflammation, Chronic Active	6 [3.3]
Inflammation, Granulomatous	
Inflammation, Pyogranulomat	
Inflammation, Suppurative	22 [3.9]
Necrosis	6 [2.7]
MUSCULOSKELETAL SYSTEM	
Bone, Cranium	(0)
Bone, Femur	(50)
Hyperostosis	
Necrosis	
Skeletal Muscle	(2)
Cyst	1
Fibrosis	1 [4.0]
NERVOUS SYSTEM	
Brain, Brain Stem	(48)
Autolysis	
Compression	2 [2.0]
Cyst	
Gliosis	
Hemorrhage	
Brain, Cerebellum	(48)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Autolysis	
Gliosis	
Hemorrhage	
Hydrocephalus	
Brain, Cerebrum	(48)
Autolysis	
Compression	
Developmental Malformation	
Ectopic Tissue	
Gliosis	
Hemorrhage	
Hydrocephalus	1 [1.0]
Infiltration Cellular, Lymphocyte	
Meninges, Congestion	
Meninges, Fibrosis	1 [2.0]
Meninges, Hemorrhage	
Mineralization	
RESPIRATORY SYSTEM	
Lung	(49)
Alveolar Epith, Hyperplasia	2 [1.5]
Artery, Mineralization	5 [1.4]
Autolysis	3 [2.7]
Congestion	1 [4.0]
Cyst	
Edema	
Hemorrhage	2 [3.5]
Infiltration Cellular, Histiocyte	21 [1.6]
Infiltration Cellular, Histiocytic	
Infiltration Cellular, Lymphocyte	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

Lab: NCTR

CD Rat MALE	F1 500PPM/CTL
Inflammation, Chronic	
Inflammation, Suppurative	
Metaplasia, Osseous	3 [1.7]
Peribronchial, Hyperplasia, Lymphoid	
Pigmentation	
Pleura, Fibrosis	
Pleura, Hyperplasia	
Pleura, Inflammation, Chronic	
Polyarteritis	
Nose	(48)
Autolysis	
Cyst	1
Foreign Body	
Fungus	
Hemorrhage	
Hyperkeratosis	
Inflammation, Chronic Active	
Inflammation, Suppurative	1 [1.0]
Keratin Cyst	
Metaplasia, Osseous	
Necrosis	
Squam Epithel, Hyperplasia	
Squam Epithel, Metaplasia	
Ulcer	
Upper Molar, Inflammation, Chronic Active	
Trachea	(48)
Cyst, Squamous	1
Epithelium, Hyperplasia	

SPECIAL SENSES SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Ear	(1)
Eye	(40)
Antr Chamber, Hemorrhage	
Antr Chamber, Inflammation, Suppurative	
Bilateral, Retina, Atrophy	1 [1.0]
Cataract	
Cornea, Degeneration	
Cornea, Inflammation, Suppurative	
Cornea, Ulcer	
Inflammation, Chronic	
Inflammation, Chronic Active	
Inflammation, Suppurative	1 [3.0]
Retina, Atrophy	1 [2.0]
Harderian Gland	(41)
Degeneration	1 [1.0]
Epithelium, Hyperplasia	
Infiltration Cellular, Lymphocyte	6 [1.0]
Inflammation, Chronic	
Pigmentation	
Lacrimal Gland	(5)
Degeneration	
Ectopic Harderian	5
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic Active	
Zymbal's Gland	(0)
Inflammation, Suppurative	
URINARY SYSTEM	
Kidney	(49)
Accumulation, Hyaline Droplet	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat MALE	F1 500PPM/CTL
Autolysis	3 [3.3]
Bacterium	
Capsule, Fatty Change	3
Capsule, Fibrosis	
Congestion	
Cortex, Cyst	24
Fatty Change	
Fibrosis	1 [1.0]
Hyperplasia, Tubular	
Infiltration Cellular, Lymphocyte	3 [1.3]
Inflammation, Chronic	
Inflammation, Chronic Active	
Inflammation, Suppurative	
Medulla, Cyst	
Mineralization	
Nephropathy, Chronic	40 [1.7]
Pelvis, Dilatation	1 [3.0]
Pelvis, Hyperplasia	4 [1.5]
Pelvis, Inflammation, Suppurative	
Pelvis, Mineralization	
Polyarteritis	
Polycystic Kidney	
Renal Tubule, Dilatation	
Renal Tubule, Inflammation, Suppurative	1 [2.0]
Renal Tubule, Mineralization	2 [1.5]
Urethra	(2)
Congestion	
Urinary Bladder	(47)
Autolysis	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:28

Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

First Dose M/F: NA / NA

CAS Number: 446-72-0

Lab: NCTR

CD Rat MALE	F1 500PPM/CTL
Dilatation	2 [4.0]
Hemorrhage	
Inflammation, Chronic Active	
Transit Epithe, Hyperplasia	

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:28

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:28

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CT
Disposition Summary						
Animals Initially In Study	54	50	50	49	50	50
Early Deaths						
Moribund	24	14	18	20	12	14
Natural Death	3	7	6	6	6	3
Survivors						
Moribund	1		3	1		
Natural Death		1	1	1	1	1
Terminal Sacrifice	26	28	22	21	31	32
Animals Examined Microscopically	54	50	50	49	50	50
ALIMENTARY SYSTEM						
Esophagus	(54)	(50)	(49)	(49)	(50)	(50)
Lumen, Dilatation				1 [3.0]		
Intestine Large	(0)	(0)	(0)	(0)	(0)	(1)
Intestine Large, Cecum	(54)	(50)	(50)	(49)	(49)	(50)
Inflammation					2 [1.0]	
Intestine Large, Colon	(54)	(50)	(50)	(49)	(50)	(49)
Intestine Large, Rectum	(30)	(32)	(30)	(24)	(33)	(36)
Intestine Small	(0)	(0)	(0)	(0)	(0)	(1)
Hyperplasia, Lymphoid						1 [1.0]
Intestine Small, Duodenum	(53)	(50)	(48)	(48)	(50)	(50)
Intestine Small, Ileum	(53)	(49)	(47)	(45)	(49)	(48)
Intestine Small, Jejunum	(54)	(49)	(47)	(45)	(49)	(48)
Inflammation				1 [3.0]		
Liver	(54)	(50)	(50)	(49)	(50)	(50)
Angiectasis		1 [1.0]	4 [1.3]	2 [1.0]	6 [2.2]	4 [1.8]
Atypical Cells				1 [2.0]		
Basophilic Focus	4	7	3	7	5	7

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 0PPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CT
Bile Duct, Hyperplasia	22 [1.3]	13 [1.3]	15 [1.5]	10 [1.2]	15 [1.2]	18 [1.2]
Biliar Tract, Fibrosis	4 [1.3]	1 [2.0]	4 [1.8]	1 [2.0]	6 [1.5]	
Clear Cell Focus	1					
Congestion		1 [2.0]				
Cyst			1	2	1	1
Degeneration, Cystic	1 [1.0]		2 [1.0]			1 [1.0]
Developmental Malformation		2	1			2
Eosinophilic Focus		4	4	2	2	1
Fibrosis					1 [1.0]	
Hematopoietic Cell Proliferation	6 [1.2]	1 [1.0]	2 [1.0]	4 [1.0]	2 [1.0]	1 [1.0]
Hepatodiaphragmatic Nodule	1	1		1		
Infiltration Cellular, Lymphocyte	2 [1.0]		4 [1.0]	2 [1.0]	4 [1.3]	
Inflammation, Chronic Active	4 [1.0]	3 [1.0]	3 [2.0]	2 [1.5]	1 [1.0]	4 [1.5]
Mixed Cell Focus		1		1		
Necrosis	1 [1.0]	2 [1.0]				2 [2.5]
Polyarteritis	1 [1.0]					
Tension Lipidosis	1 [2.0]	1 [2.0]			1 [2.0]	
Vacuolization Cytoplasmic	5 [1.2]	3 [1.7]	10 [1.1]	2 [1.0]	8 [1.4]	2 [2.0]
Vacuolization Cytoplasmic, Focal		2		2	3	3
Mesentery	(1)	(2)	(1)	(2)	(2)	(0)
Fat, Necrosis		1 [2.0]	1 [2.0]	2 [2.0]	2 [2.0]	
Pancreas	(54)	(50)	(50)	(48)	(50)	(50)
Acinar Cell, Degeneration	21 [1.4]	13 [1.9]	20 [1.7]	9 [1.3]	18 [1.7]	11 [1.7]
Acinar Cell, Hyperplasia		1 [1.0]			1 [2.0]	
Inflammation						
Polyarteritis					1 [3.0]	
Salivary Glands	(54)	(50)	(50)	(49)	(50)	(50)
Atrophy	1 [2.0]					
Parotid GI, Inflammation				1 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Submandibul GI, Inflammation			1 [1.0]			1 [1.0]
Stomach, Forestomach	(54)	(50)	(50)	(49)	(49)	(49)
Diverticulum					1 [2.0]	
Hyperplasia	3 [1.7]		1 [2.0]		2 [2.5]	1 [3.0]
Inflammation		1 [1.0]			1 [2.0]	
Keratin Cyst			1			
Ulcer	1 [2.0]		1 [4.0]	2 [2.5]	1 [2.0]	1 [3.0]
Stomach, Glandular	(54)	(50)	(50)	(49)	(50)	(50)
Erosion			1 [1.0]	1 [2.0]		
Tongue	(0)	(0)	(0)	(0)	(1)	(0)
CARDIOVASCULAR SYSTEM						
Blood Vessel	(53)	(50)	(50)	(49)	(50)	(50)
Mineralization		1 [4.0]	1 [2.0]			
Heart	(54)	(50)	(50)	(49)	(50)	(50)
Atrium Rgt, Dilatation		1 [3.0]				
Cardiomyopathy	26 [1.0]	30 [1.2]	24 [1.3]	26 [1.3]	23 [1.2]	26 [1.2]
Inflammation				1 [2.0]		
Mineralization			1 [3.0]			
ENDOCRINE SYSTEM						
Adrenal Cortex	(54)	(50)	(50)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule				1		
Angiectasis	3 [1.0]	1 [1.0]	3 [1.7]	5 [1.0]		1 [1.0]
Atrophy		1 [3.0]	1 [4.0]	1 [2.0]		
Degeneration, Cystic	45 [2.0]	45 [1.8]	42 [1.9]	42 [2.1]	46 [1.7]	45 [1.8]
Hematopoietic Cell Proliferation	1 [2.0]	1 [1.0]	1 [1.0]			
Hyperplasia	11 [1.3]	18 [1.3]	16 [1.3]	9 [1.4]	12 [1.3]	15 [1.3]
Hypertrophy	16 [1.8]	16 [2.3]	18 [1.6]	14 [1.6]	28 [1.9]	18 [2.0]
Infarct				1 [3.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Vacuolization Cytoplasmic				1 [1.0]	2 [2.5]	
Adrenal Medulla	(54)	(48)	(50)	(48)	(48)	(50)
Hyperplasia, Diffuse			1 [3.0]			1 [3.0]
Hyperplasia, Focal	3 [1.3]	3 [1.3]	7 [1.6]	2 [2.0]	7 [1.6]	5 [1.4]
Infiltration Cellular, Eosinophil		1 [3.0]				
Islets, Pancreatic	(54)	(50)	(50)	(48)	(50)	(50)
Hyperplasia		1 [1.0]	2 [1.0]		2 [1.0]	
Parathyroid Gland	(46)	(46)	(46)	(44)	(47)	(42)
Hyperplasia, Diffuse	1 [2.0]					
Hyperplasia, Focal	2 [1.0]	2 [2.0]	1 [1.0]	1 [3.0]	2 [2.0]	1 [1.0]
Pituitary Gland	(54)	(50)	(50)	(49)	(49)	(50)
Angiectasis	1 [3.0]					
Cyst	1	2	1		2	1
Infiltration Cellular, Histiocyte			1 [3.0]			
Pars Distalis, Hyperplasia	5 [2.2]	6 [1.5]	13 [1.8]	1 [1.0]	6 [2.0]	6 [1.7]
Thyroid Gland	(54)	(50)	(49)	(49)	(50)	(50)
C Cell, Hyperplasia	3 [1.0]	1 [1.0]	3 [1.3]	3 [1.3]	2 [1.5]	1 [1.0]
Cyst, Squamous	5 [1.2]	4 [1.3]	9 [1.1]	5 [1.4]	7 [1.3]	7 [1.0]
Follicular Cel, Atrophy		2 [2.0]				1 [2.0]
Follicular Cel, Hyperplasia		1 [1.0]				
GENERAL BODY SYSTEM						
Tissue NOS	(0)	(0)	(0)	(0)	(0)	(0)
GENITAL SYSTEM						
Clitoral Gland	(51)	(49)	(49)	(49)	(49)	(49)
Duct, Dilatation	7 [2.9]	9 [2.7]	8 [2.3]	6 [2.3]	6 [2.5]	7 [2.6]
Hyperplasia	2 [1.5]	3 [1.7]	1 [2.0]	1 [2.0]		3 [1.0]
Inflammation	32 [1.9]	28 [1.8]	21 [2.0]	23 [1.7]	24 [1.6]	29 [1.5]
Parenchym Cell, Degeneration	5 [2.6]	3 [2.3]	1 [1.0]	6 [2.2]	1 [2.0]	2 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Ovary	(54)	(50)	(50)	(49)	(50)	(49)
Angiectasis			2 [1.5]			
Atrophy	34 [2.5]	32 [2.3]	29 [2.2]	40 [2.4]	24 [2.0]	28 [2.0]
Cyst	11	12	14	13	9	16
Granulosa Cell, Hyperplasia						2 [2.5]
Hyperplasia, Stromal	25 [1.8]	19 [1.6]	30 [2.0]	19 [1.8]	25 [2.0]	21 [1.5]
Serosa, Hyperplasia						
Oviduct	(54)	(50)	(49)	(49)	(50)	(49)
Uterus	(54)	(50)	(50)	(49)	(50)	(49)
Angiectasis			2 [1.5]	1 [1.0]		
Atrophy			1 [3.0]			
Cervix, Muscularis, Hypertrophy	1	1	2			
Hemorrhage		1 [1.0]				
Hyperplasia, Cystic	16 [1.8]	24 [1.7]	16 [2.2]	24 [2.0]	15 [1.6]	26 [1.5]
Hyperplasia, Focal				1 [2.0]		
Inflammation	1 [2.0]					
Metaplasia	4 [1.8]	5 [1.8]	8 [1.4]	5 [1.0]	1 [1.0]	5 [1.8]
Necrosis			1 [3.0]			
Vagina	(54)	(50)	(50)	(48)	(49)	(48)
Developmental Malformation				1		
Hyperplasia				1 [2.0]		
Inflammation	4 [1.5]	3 [2.0]	5 [1.2]	7 [1.7]	3 [2.0]	2 [2.5]
Keratin Cyst	2 [2.0]					
HEMATOPOIETIC SYSTEM						
Bone Marrow	(54)	(50)	(50)	(48)	(50)	(50)
Hypocellularity	2 [3.0]	1 [3.0]	2 [2.0]	2 [2.5]	1 [2.0]	
Myeloid Cell, Hyperplasia				2 [2.0]		
Lymph Node	(11)	(10)	(12)	(5)	(9)	(10)
Axillary, Degeneration, Cystic						1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 0PPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Axillary, Infiltration Cellular, Plasma Cell						1 [1.0]
Degeneration, Cystic				1 [1.0]		
Infiltration Cellular, Plasma Cell				1 [2.0]		
Inguinal, Infiltration Cellular, Plasma Cell	1 [3.0]					
Lumbar, Degeneration, Cystic	4 [2.8]	4 [1.8]	4 [3.0]	3 [2.0]	6 [2.2]	4 [2.3]
Lumbar, Hemorrhage			1 [1.0]			
Lumbar, Hyperplasia, Lymphoid	1 [1.0]	1 [3.0]				
Lumbar, Infiltration Cellular, Plasma Cell	6 [2.2]	6 [2.0]	4 [2.3]	3 [2.7]	6 [2.3]	7 [2.3]
Mediastinal, Hemorrhage						
Mediastinal, Infiltration Cellular, Plasma Cell						
Pancreatic, Hemorrhage			1 [2.0]	1 [1.0]		
Pancreatic, Infiltration Cellular, Plasma Cell		1 [1.0]				
Pancreatic, Inflammation, Granulomatous			1 [2.0]			
Pancreatic, Pigmentation			1 [3.0]			
Popliteal, Hyperplasia, Lymphoid		1 [3.0]				
Popliteal, Infiltration Cellular, Plasma Cell		2 [2.0]	3 [2.0]		2 [2.0]	
Renal, Degeneration, Cystic				1 [2.0]		2 [3.0]
Renal, Infiltration Cellular, Plasma Cell		1 [2.0]		1 [3.0]	1 [2.0]	
Thoracic, Infiltration Cellular, Plasma Cell					1 [2.0]	
Thoracic, Thrombosis			1 [3.0]			
ymph Node, Mandibular	(53)	(50)	(50)	(49)	(50)	(50)
Cyst						1 [2.0]
Degeneration, Cystic	1 [1.0]	1 [3.0]	3 [2.0]	2 [3.0]	2 [1.0]	1 [2.0]
Hemorrhage	1 [2.0]			1 [1.0]	1 [2.0]	1 [2.0]
Hyperplasia, Lymphoid			1 [3.0]			
Infiltration Cellular, Plasma Cell	41 [1.8]	40 [1.8]	43 [1.7]	44 [1.9]	38 [1.7]	43 [1.6]
ymph Node, Mesenteric	(54)	(50)	(50)	(48)	(50)	(50)
Degeneration, Cystic		1 [2.0]	1 [4.0]			2 [3.0]
Hemorrhage				2 [1.5]	1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Hyperplasia, Lymphoid		2 [3.0]				
Inflammation, Granulomatous	44 [1.5]	42 [1.7]	42 [1.6]	44 [1.7]	46 [1.7]	47 [1.9]
Spleen	(54)	(50)	(50)	(49)	(50)	(50)
Hematopoietic Cell Proliferation	15 [2.1]	9 [1.8]	12 [2.0]	12 [1.8]	5 [1.8]	8 [1.8]
Hemorrhage						
Inflammation, Chronic Active, Focal			1 [3.0]			
Lymphocyte, Atrophy	1 [1.0]	2 [1.5]	5 [2.2]	6 [2.0]	3 [2.0]	3 [2.7]
Pigmentation	31 [1.9]	26 [1.7]	28 [1.8]	41 [2.1]	28 [1.9]	19 [1.8]
Red Pulp, Atrophy			1 [2.0]			
Red Pulp, Hyperplasia						
Thymus	(50)	(43)	(43)	(44)	(47)	(47)
Atrophy	9 [1.3]	7 [1.9]	7 [2.4]	12 [2.3]	10 [1.9]	9 [2.6]
Cyst	15 [1.3]	10 [1.6]	16 [1.3]	17 [1.8]	17 [1.9]	13 [1.5]
Ectopic Thyroid			1			
Epithel Cell, Hyperplasia	1 [2.0]	1 [1.0]	1 [1.0]	3 [2.0]	2 [2.5]	2 [1.5]
Hemorrhage	1 [2.0]	1 [2.0]	2 [2.5]	1 [2.0]	1 [3.0]	
Hyperplasia, Lymphoid				1 [3.0]		
INTEGUMENTARY SYSTEM						
Mammary Gland	(54)	(50)	(50)	(49)	(50)	(50)
Alveolus, Degeneration				2 [2.5]		
Alveolus, Hyperplasia	13 [1.5]	11 [1.5]	11 [1.9]	11 [2.0]	14 [1.4]	10 [1.1]
Atypical Focus	13	4	6	5	2	7
Duct, Hyperplasia						1 [3.0]
Galactocele	3 [2.3]	1 [3.0]	2 [3.0]	2 [1.5]	2 [2.5]	
Inflammation						
Lactation	30 [1.6]	31 [1.4]	35 [1.6]	42 [1.5]	28 [1.4]	33 [1.5]
Skin	(54)	(50)	(50)	(49)	(50)	(50)
Cyst Epithelial Inclusion					1	
Foot, Inflammation, Chronic	36 [2.4]	34 [2.6]	32 [2.4]	33 [2.3]	35 [2.6]	36 [2.8]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Inflammation					1 [2.0]	
Lip, Inflammation, Chronic					1 [3.0]	1 [3.0]
MUSCULOSKELETAL SYSTEM						
Bone, Femur	(54)	(50)	(50)	(49)	(50)	(50)
Hyperostosis	1 [2.0]					
Bone, Mandible	(0)	(0)	(0)	(0)	(1)	(0)
Bone, Tibia	(0)	(0)	(0)	(0)	(0)	(0)
Malformation						
Skeletal Muscle	(0)	(1)	(1)	(0)	(1)	(1)
NERVOUS SYSTEM						
Brain, Brain Stem	(54)	(50)	(50)	(49)	(50)	(50)
Compression	19 [1.9]	18 [1.8]	24 [2.0]	35 [1.8]	15 [2.0]	17 [1.9]
Brain, Cerebellum	(53)	(50)	(50)	(49)	(49)	(50)
Brain, Cerebrum	(54)	(50)	(50)	(49)	(50)	(50)
Hemorrhage						2 [2.5]
Hydrocephalus	2 [2.0]			3 [2.0]	3 [1.7]	2 [1.5]
RESPIRATORY SYSTEM						
Lung	(54)	(50)	(50)	(49)	(50)	(50)
Alveolar Epith, Hyperplasia		1 [2.0]	2 [2.0]			
Atelectasis					1 [2.0]	
Hemorrhage		1 [3.0]				
Infiltration Cellular, Histiocyte	9 [1.4]	17 [1.7]	13 [1.5]	17 [1.2]	12 [1.4]	12 [1.6]
Inflammation			1 [2.0]		1 [3.0]	
Metaplasia					1 [2.0]	
Nose	(54)	(50)	(50)	(49)	(50)	(50)
Foreign Body				1		
Fungus					1	
Inflammation			3 [1.0]	2 [2.0]	4 [2.0]	1 [4.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 17:23:29

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:29

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Keratin Cyst				2	1	
Nasolacrim Dct, Inflammation	7 [1.6]	7 [1.7]	6 [1.7]	7 [1.4]	2 [1.0]	
Upper Molar, Inflammation	1	1	5	3	3	2
Trachea	(54)	(50)	(50)	(49)	(50)	(50)
SPECIAL SENSES SYSTEM						
Ear	(0)	(0)	(0)	(0)	(2)	(0)
Hemorrhage					1 [2.0]	
Eye	(32)	(32)	(31)	(26)	(33)	(37)
Bilateral, Lens, Cataract		1 [1.0]	2 [2.0]		1 [1.0]	3 [2.3]
Bilateral, Retina, Degeneration	3 [2.7]	3 [2.0]	1 [3.0]	1 [3.0]	1 [2.0]	2 [2.5]
Cornea, Ulcer						
Lens, Cataract				2 [2.0]		
Lens, Unilateral, Cataract	1 [4.0]					
Phthisis Bulbi				1		
Polyarteritis						1 [1.0]
Retina, Degeneration	2 [1.5]	1 [2.0]	3 [1.7]	3 [1.7]	4 [1.5]	5 [2.6]
Retina, Unilateral, Degeneration	1 [3.0]					
Harderian Gland	(30)	(34)	(30)	(25)	(33)	(36)
Epithelium, Degeneration	6 [1.0]	20 [1.3]	9 [1.4]	10 [1.8]	18 [1.6]	17 [1.7]
Hypertrophy	3 [1.3]	3 [1.0]	4 [1.5]	3 [1.0]	3 [1.3]	4 [1.5]
Lacrimal Gland	(0)	(1)	(1)	(1)	(1)	(0)
Metaplasia		1 [2.0]		1 [3.0]	1 [2.0]	
URINARY SYSTEM						
Kidney	(54)	(50)	(50)	(49)	(50)	(50)
Accumulation, Hyaline Droplet	2 [3.0]	1 [3.0]				
Cyst	14	17	13	13	12	16
Epithelium, Pelvis, Hyperplasia	1 [2.0]		1 [2.0]		1 [2.0]	1 [2.0]
Hydronephrosis	2 [2.0]					

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 OPPM	F1 5PPM	F1 100PPM	F1 500PPM	F1 5PPM/CTL	F1 100PPM/CTL
Infarct	1 [1.0]	3 [1.0]	1 [2.0]		2 [2.0]	1 [1.0]
Inflammation	2 [1.0]		1 [2.0]	1 [2.0]		3 [1.3]
Nephropathy	13 [1.2]	10 [1.7]	12 [1.4]	17 [1.4]	13 [1.5]	5 [1.6]
Pelvis, Mineralization	16 [1.2]	20 [1.4]	23 [1.3]	25 [1.2]	20 [1.5]	21 [1.3]
Renal Tubule, Mineralization	38 [1.5]	37 [1.6]	36 [1.8]	37 [1.5]	36 [1.9]	33 [1.7]
Renal Tubule, Pigmentation				1 [2.0]		
Urinary Bladder	(54)	(49)	(49)	(49)	(49)	(48)
Developmental Malformation				1		
Hyperplasia		1 [1.0]	1 [3.0]			
Inflammation			1 [1.0]			
Mineralization						1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 500PPM/CTL
Disposition Summary	
Animals Initially In Study	50
Early Deaths	
Moribund	18
Natural Death	9
Survivors	
Moribund	
Natural Death	
Terminal Sacrifice	23
Animals Examined Microscopically	50
ALIMENTARY SYSTEM	
Esophagus	(50)
Lumen, Dilatation	
Intestine Large	(0)
Intestine Large, Cecum	(50)
Inflammation	
Intestine Large, Colon	(50)
Intestine Large, Rectum	(26)
Intestine Small	(0)
Hyperplasia, Lymphoid	
Intestine Small, Duodenum	(50)
Intestine Small, Ileum	(47)
Intestine Small, Jejunum Inflammation	(49)
Liver	(50)
Angiectasis	2 [1.0]
Atypical Cells	
Basophilic Focus	6

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 500PPM/CTL
Bile Duct, Hyperplasia	13 [1.5]
Biliar Tract, Fibrosis	2 [1.5]
Clear Cell Focus	
Congestion	
Cyst	3
Degeneration, Cystic	1 [1.0]
Developmental Malformation	
Eosinophilic Focus	4
Fibrosis	
Hematopoietic Cell Proliferation	1 [1.0]
Hepatodiaphragmatic Nodule	2
Infiltration Cellular, Lymphocyte	1 [1.0]
Inflammation, Chronic Active	2 [1.5]
Mixed Cell Focus	
Necrosis	2 [2.0]
Polyarteritis	
Tension Lipidosis	
Vacuolization Cytoplasmic	3 [1.3]
Vacuolization Cytoplasmic, Focal	
Mesentery	(2)
Fat, Necrosis	2 [2.0]
Pancreas	(50)
Acinar Cell, Degeneration	14 [1.2]
Acinar Cell, Hyperplasia	
Inflammation	1 [1.0]
Polyarteritis	1 [1.0]
Salivary Glands	(50)
Atrophy	1 [3.0]
Parotid GI, Inflammation	2 [2.5]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1	500PPM/CTL
Submandibul GI, Inflammation		
Stomach, Forestomach		(50)
Diverticulum		
Hyperplasia		2 [2.0]
Inflammation		1 [2.0]
Keratin Cyst		
Ulcer		1 [1.0]
Stomach, Glandular		(50)
Erosion		
Tongue		(0)
CARDIOVASCULAR SYSTEM		
Blood Vessel		(50)
Mineralization		(00)
Heart		(50)
Atrium Rgt, Dilatation		()
Cardiomyopathy		28 [1.2]
Inflammation		
Mineralization		
ENDOCRINE SYSTEM		
Adrenal Cortex		(50)
Accessory Adrenal Cortical Nodule		(00)
Angiectasis		1 [1.0]
Atrophy		. []
Degeneration, Cystic		45 [2.0]
Hematopoietic Cell Proliferation		- 1
Hyperplasia		11 [1.3]
Hypertrophy		18 [1.9]
Infarct		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 500PPM/CTL
Vacuolization Cytoplasmic	1 [3.0]
Adrenal Medulla	(48)
Hyperplasia, Diffuse	
Hyperplasia, Focal	5 [1.8]
Infiltration Cellular, Eosinophil	
Islets, Pancreatic	(50)
Hyperplasia	2 [2.0]
Parathyroid Gland	(43)
Hyperplasia, Diffuse	1 [2.0]
Hyperplasia, Focal	1 [2.0]
Pituitary Gland	(50)
Angiectasis	
Cyst	
Infiltration Cellular, Histiocyte	
Pars Distalis, Hyperplasia	2 [2.0]
Thyroid Gland	(50)
C Cell, Hyperplasia	2 [1.0]
Cyst, Squamous	8 [1.3]
Follicular Cel, Atrophy	1 [2.0]
Follicular Cel, Hyperplasia	1 [1.0]
GENERAL BODY SYSTEM	
Tissue NOS	(1)
GENITAL SYSTEM	(40)
Clitoral Gland	(49)
Duct, Dilatation	11 [2.5]
Hyperplasia	3 [2.0]
Inflammation	23 [2.0]
Parenchym Cell, Degeneration	2 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 500PPM/CTL
Ovary	(49)
Angiectasis	
Atrophy	42 [2.4]
Cyst	18
Granulosa Cell, Hyperplasia	
Hyperplasia, Stromal	17 [1.7]
Serosa, Hyperplasia	1 [1.0]
Oviduct	(47)
Uterus	(50)
Angiectasis	
Atrophy	
Cervix, Muscularis, Hypertrophy	2
Hemorrhage	
Hyperplasia, Cystic	33 [2.1]
Hyperplasia, Focal	1 [3.0]
Inflammation	
Metaplasia	7 [1.6]
Necrosis	
Vagina	(50)
Developmental Malformation	
Hyperplasia	
Inflammation	5 [1.8]
Keratin Cyst	
HEMATOPOIETIC SYSTEM	
Bone Marrow	(50)
Hypocellularity	1 [2.0]
Myeloid Cell, Hyperplasia	1 [2.0]
Lymph Node	(9)
Axillary, Degeneration, Cystic	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1	500PPM/CTL
Axillary, Infiltration Cellular, Plasma Cell		
Degeneration, Cystic		
Infiltration Cellular, Plasma Cell		
Inguinal, Infiltration Cellular, Plasma Cell		
Lumbar, Degeneration, Cystic		3 [1.7]
Lumbar, Hemorrhage		
Lumbar, Hyperplasia, Lymphoid		
Lumbar, Infiltration Cellular, Plasma Cell		6 [1.7]
Mediastinal, Hemorrhage		1 [2.0]
Mediastinal, Infiltration Cellular, Plasma Cell		1 [2.0]
Pancreatic, Hemorrhage		2 [2.0]
Pancreatic, Infiltration Cellular, Plasma Cell		
Pancreatic, Inflammation, Granulomatous		
Pancreatic, Pigmentation		
Popliteal, Hyperplasia, Lymphoid		
Popliteal, Infiltration Cellular, Plasma Cell		1 [2.0]
Renal, Degeneration, Cystic		1 [1.0]
Renal, Infiltration Cellular, Plasma Cell		1 [2.0]
Thoracic, Infiltration Cellular, Plasma Cell		
Thoracic, Thrombosis		
Lymph Node, Mandibular		(50)
Cyst		
Degeneration, Cystic		2 [2.0]
Hemorrhage		1 [1.0]
Hyperplasia, Lymphoid		
Infiltration Cellular, Plasma Cell		45 [1.8]
Lymph Node, Mesenteric		(50)
Degeneration, Cystic		1 [1.0]
Hemorrhage		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 500PPM/CTL
Hyperplasia, Lymphoid	
Inflammation, Granulomatous	45 [1.6]
Spleen	(50)
Hematopoietic Cell Proliferation	8 [2.0]
Hemorrhage	1 [3.0]
Inflammation, Chronic Active, Focal	
Lymphocyte, Atrophy	4 [2.5]
Pigmentation	34 [1.9]
Red Pulp, Atrophy	
Red Pulp, Hyperplasia	1 [2.0]
Thymus	(47)
Atrophy	9 [1.8]
Cyst	20 [1.7]
Ectopic Thyroid	
Epithel Cell, Hyperplasia	1 [3.0]
Hemorrhage	
Hyperplasia, Lymphoid	
INTEGUMENTARY SYSTEM	
Mammary Gland	(50)
Alveolus, Degeneration	
Alveolus, Hyperplasia	15 [1.6]
Atypical Focus	11
Duct, Hyperplasia	
Galactocele	2 [2.0]
Inflammation	1 [3.0]
Lactation	40 [1.6]
Skin	(50)
Cyst Epithelial Inclusion	
Foot, Inflammation, Chronic	35 [2.4]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 500PPM/CTL
Inflammation	
Lip, Inflammation, Chronic	
MUSCULOSKELETAL SYSTEM	
Bone, Femur	(50)
Hyperostosis	,
Bone, Mandible	(0)
Bone, Tibia	(1)
Malformation	1
Skeletal Muscle	(0)
NERVOUS SYSTEM	
Brain, Brain Stem	(50)
Compression	31 [1.9]
Brain, Cerebellum	(50)
Brain, Cerebrum	(50)
Hemorrhage	(00)
Hydrocephalus	2 [1.0]
RESPIRATORY SYSTEM	
Lung	(50)
Alveolar Epith, Hyperplasia	1 [1.0]
Atelectasis	1 [1.0]
Hemorrhage	
Infiltration Cellular, Histiocyte	20 [1.7]
Inflammation	1 [1.0]
Metaplasia	1 [1.0]
Nose	(50)
Foreign Body	(50)
Fungus	
Inflammation	4 [1.3]
	. []

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

CD Rat FEMALE	F1 500PPM/CTL
Keratin Cyst	
Nasolacrim Dct, Inflammation	4 [1.5]
Upper Molar, Inflammation	1
Trachea	(50)
SPECIAL SENSES SYSTEM	
Ear	(0)
Hemorrhage	()
Eye	(28)
Bilateral, Lens, Cataract	
Bilateral, Retina, Degeneration	
Cornea, Ulcer	1 [4.0]
Lens, Cataract	
Lens, Unilateral, Cataract	
Phthisis Bulbi	
Polyarteritis	
Retina, Degeneration	1 [2.0]
Retina, Unilateral, Degeneration	
Harderian Gland	(26)
Epithelium, Degeneration	13 [1.5]
Hypertrophy	5 [1.0]
Lacrimal Gland	(2)
Metaplasia	1 [1.0]
URINARY SYSTEM	
Kidney	(50)
Accumulation, Hyaline Droplet	
Cyst	19
Epithelium, Pelvis, Hyperplasia	
Hydronephrosis	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: DOSED FEED

Species/Strain: Rat/CD

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Date Report Requested: 10/22/2014
Time Report Requested: 17:23:30

Test Compound: Endocrine disruptor (Genistein)

CAS Number: 446-72-0

Time Report Requested: 17:23:30

First Dose M/F: NA / NA

Lab: NCTR

CD Rat FEMALE	F1 500PPM/CTL
Infarct	
Inflammation	1 [1.0]
Nephropathy	8 [1.4]
Pelvis, Mineralization	23 [1.2]
Renal Tubule, Mineralization	36 [1.7]
Renal Tubule, Pigmentation	
Urinary Bladder	(49)
Developmental Malformation	
Hyperplasia	
Inflammation	
Mineralization	

** END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)